Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis

Ziegelmeier, Michaela; Bachmann, Anette; Seeger, Jeannette; Lössner, Ulrike; Kratzsch, Jürgen; Blüher, Matthias; Stümvoll, Michael; Faßhauer, Mathias

doi:10.1016/j.metabol.2008.05.011

Cited by 23 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum resistin and adiponectin levels were 23.6 ± 9.3 µg/L and 75.5 ± 12.6 mg/L, respectively. These levels in our HD patients were higher than those of healthy subjects (serum resistin 5.8 ± 1.7 μg/L and adiponectin 6.7 ± 3.8 mg/L), as reported by other investigators (Ziegelmeier et al 2008). The EPO dose and ERI were 6,982 ± 3,299 IU/week and History of congestive heart failure 3…”

Section: Resultssupporting

confidence: 87%

Serum Resistin as a Novel Marker of Erythropoietin Resistance in Nondiabetic Patients on Hemodialysis

Chang

Jung

Lee

et al. 2011

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The use of higher erythropoietin (EPO) doses is associated with an increased risk of an adverse outcome and increased mortality in patients with renal failure. Resistin is related to heart disease, and may contribute to an increased atherosclerotic risk. We hypothesized that a link between resistin and EPO responsiveness may exist. We therefore investigated the relationship between resistin and the EPO resistance index (ERI) in nondiabetic hemodialysis (HD) patients. Fifty-seven patients enrolled in the study underwent HD for ≥ 3 months and intravenous EPO therapy to maintain a target hemoglobin (Hb) level of 11.0 g/dl. The ERI was defined as the weekly EPO dose per unit Hb per body weight. The mean patient age was 52.6 ± 11.9 years and the mean time on dialysis was 4.9 ± 4.4 years. Serum Hb and ERI were 10.4 ± 0.7 g/dl, and 13.3 ± 7.0 (IU/kg/week/g/dl), respectively. Serum resistin levels were 23.6 ± 9.3 µg/L. EPO resistance is associated with low body mass index (BMI) (coefficient β =−0.393, p = 0.002) and with high serum resistin levels (coefficient β = 0.332, p = 0.018). According to a multiple regression analysis, the serum resistin level was a significant independent factor related to EPO resistance (p = 0.017). The results suggest that serum resistin levels reflect EPO responsiveness in nondiabetic HD patients. Resistin may therefore be considered as a new marker of EPO responsiveness in HD patients.

show abstract

Section: Resultssupporting

confidence: 87%

Serum Resistin as a Novel Marker of Erythropoietin Resistance in Nondiabetic Patients on Hemodialysis

Chang

Jung

Lee

et al. 2011

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…On the contrary, such a relation was detected by others, 8,12 but not all investigators. 13 Thus the effect of inflammation on visfatin levels in HD patients remains to be elucidated.…”

Section: 2mentioning

confidence: 99%

“…6,7 Several studies have shown elevated serum visfatin level in HD and/or associations with metabolic parameters, atherosclerosis, and inflammation. [8][9][10][11][12][13] In patients with insulin resistance, iron metabolism is disturbed.…”

Section: Introductionmentioning

confidence: 99%

Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin

et al. 2013

View full text Add to dashboard Cite

“…However, it is unknown whether kidney clearance of visfatin/NAMPT exists. In patients with end-stage chronic kidney disease (CKD), a significantly increased circulating visfatin/NAMPT level using a highly specific ELISA method was found [5,6]. It should be emphasized that hemodialysis patients in both studies were characterized by significant systemic inflammation and insulin resistance.…”

Section: Introductionmentioning

confidence: 97%

Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects

Kocełak

Olszanecka-Glinianowicz

Owczarek

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

IntroductIon Visceral adipose tissue is the main source of circulating proinflammatory adipokine, visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT), whose role in the pathogenesis of metabolic syndrome (MS) components such as hypertension and carbohydrate and lipid disturbances is still uncertain, due to commonly used low specific C-terminal immunoassays to determine visfatin/ NAMPT levels. objectIves The aim of the study was to assess the association between the occurrence of MS components and circulating visfatin/NAMPT levels in elderly population. PAtIents And methods The analysis included 2174 elderly participants of the PolSenior study without heart failure, severe chronic kidney disease, cancer, and malnutrition. MS was defined according to the modified International Diabetes Federation criteria. Plasma visfatin/NAMPT concentrations were measured by a highly specific enzyme-linked immunosorbent assay. Additionally, high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), and insulin levels were assessed, and the homeostasis model assessment for insulin resistance was calculated. results Women were diagnosed with MS more often than men (71.2% vs 56.8%; P <0.001) and had a greater prevalence of all MS components except for type 2 diabetes. Women with MS had higher concentrations of hsCRP and IL-6 than those without MS. Visfatin/NAMPT concentrations were higher in women with MS than in those without MS (1.06 ng/ml [0.65-1.87] vs 0.85 ng/ml [0.54-1.40]; P <0.001), but no differences were observed in men (0.97 ng/ml [0.59-1.61] vs 0.90 ng/ml [0.56-1.60], respectively; P = 0.5). In women, there was a stronger association between the number of components of MS and increased plasma visfatin/NAMPT levels than in men. conclusIons Plasma visfatin/NAMPT levels are increased only in elderly women with MS. It is difficult to distinguish the components of MS specifically associated with increased visfatin/NAMPT levels. orIGInAl ArtIcle orIGInAl ArtIcle Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT)... 403 assay (ELISA) kits in plasma samples of a large group of elderly subjects, participants of the Pol-Senior study, 18 may provide new data on the role of visfatin/NAMPT in MS. In our recently published study, we have shown that plasma visfa-tin/NAMPT levels are associated with age, sys-temic microinflammation, and IR regardless of sex, and with nutritional status only in women. 19 The aim of the present study was to assess the association between the number and type of MS components and circulating plasma visfatin/ NAMPT levels in elderly population. PAtIents And methods study design and setting This substudy was based on 2733 banked samples from the PolSenior study 18 stored at-70°C. The PolSenior study conducted in the years 2008 and 2011 recruited 6 age cohorts of a similar size (65-69 years, 70-74 years, 75-79 years, 80-84 years, 85-89 years, and ≥90 years). Trained nurses visited a total of 4979 participants 3 times to conduct a questionnaire survey, comprehensive ger...

show abstract

Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis

Cited by 23 publications

References 25 publications

Serum Resistin as a Novel Marker of Erythropoietin Resistance in Nondiabetic Patients on Hemodialysis

Serum Resistin as a Novel Marker of Erythropoietin Resistance in Nondiabetic Patients on Hemodialysis

Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin

Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects

Contact Info

Product

Resources

About